Non-Variceal Upper Gastrointestinal Haemorrhage: Clinical Profile and Application of Rockall Prognostic Score by Raja Yogesh, K
1 
 
Non-Variceal Upper Gastrointestinal 
Haemorrhage 
- Clinical Profile and Application of 
Rockall Prognostic Score 
 
Dissertation submitted to 
THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY 
In partial fulfillment of the requirements 
for the award of the degree of 
 
M.D.  BRANCH  - I  
GENERAL MEDICINE 
 
 
INSTITUTE OF INTERNAL MEDICINE 
MADRAS MEDICAL COLLEGE &                     
GOVERNMENT GENERAL HOSPITAL,                  
CHENNAI  
 
 
 
 
THE TAMIL NADU DR. M.G.R. MEDICAL 
UNIVERSITY 
CHENNAI 
2 
 
MARCH 2009 
CERTIFICATE 
 
 
This is to certify that the dissertation titled                    
“Non-variceal Upper Gastrointestinal Haemorrhage - Clinical 
Profile and Application of Rockall Prognostic Score” is the bonafide 
original work of Dr. Raja Yogesh K., in partial fulfillment of the 
requirements for  M.D. Branch– I (General Medicine) Examination of 
the Tamilnadu Dr. M.G.R Medical University to be held in MARCH 
2009.  The Period of study was from January 2008 to September 2008. 
 
Director & HOD incharge                       PROF. M.JUBILEE, M.D.,                   
Professor of Medicine           Professor of Medicine          
Institute of Internal Medicine                      Institute of Internal Medicine
  Madras Medical College and                              Madras Medical 
College and    Government General Hospital          Government 
General Hospital Chennai                          Chennai  
 
 
 
 
Dr.   T.P. KALANITI, M.D.,                                                       
Dean                                                                      
Madras Medical College and                                                              
Government General Hospital                                                            
Chennai 
 
3 
 
        
DECLARATION 
 
 
 
I  hereby solemnly declare that the dissertation  titled                     
“Non –variceal Upper Gastrointestinal Hemorrhage – Clinical 
Profile and  Application of Rockall Prognostic Score” was done by 
me at Madras Medical College and Government General Hospital, 
Chennai-3, during January 2008 – September 2008, under the guidance 
and supervision of my unit Chief Prof. M. Jubilee, M.D.   
 
The dissertation is submitted to the Tamilnadu Dr. M.G.R. 
Medical University towards the partial fulfillment of requirements for 
the award of M.D degree (Branch-1) in General Medicine. 
 
 
 
 
 
Place:        SIGNATURE OF THE CANDIDATE  
                                                                       
Date :           
                                                                                  
4 
 
ACKNOWLEDGEMENT 
 
At the outset, I thank Prof. T. P. KALANITI, M.D., Dean, 
Madras Medical College and Government General Hospital, for having 
permitted me to use  the hospital material  for the study.   
 
I am grateful to Prof. C. RAJENDIRAN, M.D., Director and 
Head of Department- incharge, Institute of Internal Medicine, Madras 
Medical College and Government General Hospital, Chennai-3 for his 
support and guidance. 
 
I am greatly indebted to my Chief Prof. M. JUBILEE, M.D., 
Professor of Medicine, Institute of Internal Medicine, Madras Medical 
College and Government General Hospital, for her valuable suggestions, 
criticisms and encouragement during the study.  
 
I express my sincere gratitude to Prof. MOHAMMED ALI, 
M.D., D.M.(Gastro.), Professor and Head of the Department of 
Gastroenterology, Madras Medical College and Government General 
Hospital, for his immense help and support during the study. 
I would also like to thank my Asst. Professors Dr. K.V.S. 
LATHA, M.D., and Dr. PENCHALAIAH, M.D., Madras Medical 
College and Government General Hospital, for their constant help and 
encouragement. 
 
             My special thanks to all the patients in the study, for their 
participation and extreme cooperation. 
 
Lastly, I thank all my Professional colleagues for their support 
and valuable criticisms.                                                                                      
5 
 
 
 CONTENTS           PAGE NO  
 
  
          1.       INTRODUCTION           1 
                
   
         2.       AIMS OF THE STUDY         7 
              
    3.       REVIEW OF LITERATURE                         8                      
 
  4.       MATERIALS AND METHODS          29                
 
5.      RESULTS          36 
 
6.      DISCUSSION         59 
                                               
7.      CONCLUSIONS         71 
 
8.      SUGGESTIONS         72 
 
 9.       BIBLIOGRAPHY                          73        
       
  10.      APPENDIX          80 
      I.    ABBREVIATIONS & ACRONYMS 
II.     PROFORMA 
III. MASTER CHART 
           IV.    ETHICAL COMMITTEE APPROVAL ORDER 
 
6 
 
 
INTRODUCTION 
Upper Gastrointestinal haemorrhage is one of the common 
emergencies met in clinical practice. The mode of presentation is diverse 
and depends on the cause and the amount of blood loss. It can present 
with a spectrum of clinical severity that ranges from trivial and 
insignificant bleeds to fulminant and lethal exsanguinations. It is 
considered a potentially fatal emergency with a mortality rate as high as 
14%1. It accounts for up to 20,000 deaths annually in the United States. 
The overall incidence of acute gastrointestinal haemorrhage has been 
estimated to be 50 to 100 per 100,000 persons per year, with an annual 
hospitalisation of approximately 100 per 100,000 hospital admissions1. 
  The incidence of UGIH has been stable since the mid-1980s. On 
one hand, the introductions of proton pump inhibitors and efforts to 
eradicate H.pylori infection have reduced the incidence of ulcer 
bleeding. On the other hand, with the increasing average age expectancy 
of the population and with it the increasing age-related co-morbid 
conditions may predispose patients to UGIH. The increasing use and 
abuse of NSAIDs might perhaps tend to shift the balance towards an  
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increased incidence. The risk of UGIH appears to be increased in certain 
group of patients, particularly those with underlying cardiovascular 
disease, chronic renal failure and perhaps patients older than 65 years of 
age.  
  Historically, the most common cause of UGIH has been 
gastroduodenal ulcer disease, although other upper gastrointestinal 
mucosal lesions account for a substantial proportion of cases. Whatever 
the lesion be, the initial step in the management of a patient with UGIH 
is to assess the severity of bleeding. The patient’s hemodynamic status is 
the initial focal point and the basis for assessing the patient’s overall 
clinical condition. Unstable vital signs indicate that the patient is 
bleeding from a major vascular source and indicate a poorer prognosis.  
Resuscitation is of paramount importance in a bleeding patient 
and should be proportional to the severity of the bleed. In an actively 
bleeding patient, crystalloids or colloids need to be infused as rapidly as 
the patient’s cardiovascular system will allow. Virtually all patients with 
unstable vitals should be transfused. 
As the patient is being resuscitated and stabilised, the patient’s 
history and physical examination might be analysed to ascertain the 
cause and site of the bleed. History of duration of the patients symptoms 
need to be carefully analysed. The historical features important to 
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determine include the presence of abdominal pain (PUD), history of 
retching (MW tear), or a change in bowel habits, or weight loss – 
pointing towards a GI malignancy. History of alcohol intake, smoking 
habits and history of NSAID ingestion should also be enquired into. 
Previous history of UGIH and abdominal surgeries may throw light on 
the problem at hand. History and physical examination to detect the 
presence of existing co-morbid conditions should be carried out since 
they are adverse prognostic indicators in patients with UGIH. 
The primary diagnostic modality for evaluation of patients with 
UGIH is oesophagogastroduodenoscopy. The endoscopic appearance of 
the lesions and the presence of stigmata of bleed have an important role 
in predicting the course and outcome of the patients. 
The major goal of treatment is to stop the bleeding and prevent 
rebleeding. The major forms of therapy include 1) pharmacological, 2) 
endoscopic therapy, 3) angiographic and 4) surgical. The use of each of 
these modalities depends on the cause of the cause of bleeding. For 
patients with significant bleeding, the mainstay of treatment of bleeding 
lesions is endoscopic therapy. Indeed, it is the major justification for 
oesophagogastroduodenoscopy in those with hemodynamically 
significant acute upper gastrointestinal bleeding, since endoscopic 
therapy unquestionably improves prognosis3 . For this reason, such 
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patients should undergo the procedure as early as possible. In addition, 
the endoscopic appearance of certain lesions may help triage patients, 
and thereby reduce costs of hospitalization.  A proposed approach to 
patients with UGIH is as follows... 
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The prognosis of patients with UGIH is as varied as the 
presentation. A number of prognostic scoring systems have been 
developed to predict the outcome and course of the patients. One such 
prognostic scoring system is The Rockall Scoring System. 
Government General Hospital, Chennai, a tertiary referral centre, 
receives approximately 800-1000 patients/year with UGIH. In these 
patients, hospital admission is regarded as compulsory since there is a 
chance of these patients having continued bleeding or rebleeding. A very 
large proportion of these patients are actually at a very low risk for 
rebleeding and mortality. Identifying these patients and stratifying them 
according to their risks would help in their appropriate management. In 
those with a low risk of an adverse outcome, an early discharge can be 
planned and in those with a high risk, a more intensive monitoring can 
be provided. It is aimed that such stratification would lead to a reduction 
of hospital expenses in the former group (by means of an early 
discharge) and more intensive management in the latter group. It is 
believed that this would result in substantial resource savings both for 
the patient (in-hospital expenses), as well as the State, without 
compromising on the standard of health care. In this study, The Rockall 
Scoring System is used for stratifying patients with NVUGIH and the 
usefulness of the same in predicting the outcome is analysed. 
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AIMS OF THE STUDY 
 
      To study the Clinical presentation, etiologies, and outcome of  
patients admitted with Upper Gastrointestinal bleeding of a  
Non-Variceal cause. 
 
      To correlate the Rockall Score of these patients with 
1. The event of Re-bleed,  
2. Transfusion requirements, 
3. Duration of hospitalisation   and 
4. Their final Outcome. 
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REVIEW OF LITERATURE 
DEFINITION   
Upper gastrointestinal haemorrhage is defined as any bleeding 
from a site in the gastrointestinal tract proximal to the ligament of Treitz 
(fore-gut). 
PRESENTATION  
Patients with Upper gastrointestinal haemorrhage present with a 
wide range of clinical severity ranging from trivial bleeds to fulminant 
and lethal exsanguinations. They can present with one or more of the 
following symptoms... 
 Haematemesis :  It is defined as the vomiting of blood which can be 
fresh and bright red in colour or it may be old and take the form of 
coffee grounds. It indicates an upper gastrointestinal source (defined as 
the gastrointestinal segment proximal to the ligament of Treitz). 
Spurious haematemesis can occur due to vomiting of swallowed blood 
from a source in the respiratory tract. 
Melaena:  Melaena is defined as the passage of black, tarry, and foul 
smelling stools. The black tarry nature is due to the degradation of the 
blood to haematin and other haemochromes by the colonic bacteria.       
A minimum of at least 50ml of blood is required to produce melaena 
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though volumes up to 100 ml may be clinically silent.  For melaena to 
develop, blood has to be present for at least 14 hours within the GI tract. 
Thus, the more proximal the bleed, the more likely melaena would 
occur.  Melaena, unlike haematemesis, is not specific for UGIH since 
melaena can also occur due to bleeding from the small bowel as well as 
slow bleeds from the ascending colon. Melaena should be differentiated 
from dark stools secondary to ingested iron or bismuth. These stools 
though dark are not tarry or offensive. 
Haematochezia: It refers to the passage of bright red blood from the 
rectum that may or may not be mixed with stools. Although 
haematochezia is predominantly a symptom of lower gastrointestinal 
bleeding, it can occur in up to 10% of patients with UGIH, especially 
when the haemorrhage is brisk and haemodynamically significant.    
         Occult bleeding is defined as bleeding from the GI tract that is not 
apparent to the patient. It usually results from small amounts and 
haemodynamically insignificant bleed. Bleeding of obscure origin can 
be occult or obvious (e.g., manifest by haematemesis, melaena, or 
haematochezia), but from a source that is difficult to pinpoint on routine 
examination. These two forms of presentation are not considered in the 
study for reasons that are obvious.  
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Non-variceal bleeding forms the majority (90%) of the cases with 
UGIH3,4. The causes of NVUGIH are varied, and are listed below... 
CAUSES OF NVUGIH  
COMMON LESS COMMON RARE 
Gastric ulcer 
Duodenal ulcer 
Mallory-Weiss tear 
 
Gastric erosions/gastropathy 
Oesophagitis 
Cameron lesions 
Dieulafoy lesion 
Telangiectasias 
Portal hypertensive  
gastropathy 
Gastric antral vascular 
ectasias 
Gastric varices 
Neoplasms 
Oesophageal ulcer 
Erosive duodenitis 
Aortoenteric fistula 
Haemobilia 
Pancreatic disease 
Crohn’s disease 
 
 
OESOPHAGITIS 
Significant bleeding from oesophagitis accounts for up to 8% of 
patients with UGIH. Bleeding from oesophagitis more commonly causes 
occult blood loss than acute bleeding. Clinically obvious bleeding is 
most likely in those with extensive ulcerative disease or with an 
underlying coagulopathy. Specific therapy is directed at the cause of the 
underlying lesion (usually reflux oesophagitis), and typically involves 
high-dose proton pump inhibitors. Endoscopic treatment of bleeding 
lesions may benefit patients with oesophageal ulcerations and visible 
vessels, but because of the risk for perforation, it should be performed 
with caution. 
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MALLORY-WEISS TEAR 
          Mallory-Weiss tears are lacerations in the region of the 
gastroesophageal junction that typically occur in gastric mucosa, 
although 10% to 20% can occur in oesophageal mucosa. They are an 
important cause and account for approximately 5% to 10% of cases of 
upper UGIH.1,3,5,6 Although they are thought to be caused by retching, a 
history of this is obtained in only 29% of patients.7 Bleeding from 
Mallory-Weiss tears stops spontaneously in 80% to 90% of patients, and 
less than 5% of patients rebleed. Patients not bleeding during endoscopy 
and without other medical problems that require hospitalization are 
usually managed with supportive care only and can be discharged 
promptly. Endoscopic therapy with coagulation methods, injection, or 
banding effectively stops bleeding and should be performed on bleeding 
lesions or patients with bleeding stigmata. Angiographic therapy, with 
intra-arterial infusion of vasopressin, or embolization is successful in a 
high proportion of patients. Surgical therapy is rarely required. 
DUODENAL AND GASTRIC ULCERS 
         Ulcer disease is the most common cause of acute UGIH. In a study 
done by Skok P et al.,  it was shown that gastroduodenal ulcers were 
responsible for UGIH  in nearly 50% of cases.8 The incidence of 
bleeding from duodenal ulcers is approximately twofold that of gastric 
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ulcers. The hospitalization rate for ulcer-related gastrointestinal bleeding 
appears to be constant at approximately 40 to 60 cases per 100,000 
patients.1,4,9 
Ulcers bleed when they erode into the lateral wall of a vessel. 
Ulcers located high on the lesser curve of the stomach or on the 
posteroinferior wall of the duodenal bulb are most likely to bleed (and 
rebleed), presumably due to the rich vascular supply in these areas. The 
precise pathophysiology of ulcer bleeding is unclear, but is likely to 
encompass factors related to the bleeding blood vessel itself, as well as 
factors related to the ulcer environment. 
PREDISPOSING FACTORS FOR ULCER BLEEDING 
A number of risk factors predispose to ulcer disease and its 
bleeding, the most prominent being acid, Helicobacter pylori, and 
nonsteroidal anti-inflammatory drugs (NSAIDs). In addition, underlying 
medical and clinical factors predispose to ulcer disease and bleeding. In 
a case control study of 1122 patients and 2231 controls done by Lanas  
et al10, cardiovascular and cerebrovascular disease were independent 
predictors of peptic ulcer–related UGIH. Chronic pulmonary disease and 
cirrhosis also are associated with peptic ulcer disease. Pharmacologic 
agents besides aspirin and NSAIDs may predispose to ulcer disease. 
Glucocorticoids historically have been associated with an increased risk 
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of peptic ulcer, although newer data raise doubt about this association. 
Recent data link alendronate to the development of gastric ulcers and 
perhaps upper gastrointestinal bleeding.  Also, ethanol may potentiate 
the damaging effects of NSAIDs in the mucosa, and, as expected, 
anticoagulants will facilitate bleeding. 
Hospitalization appears to be an important risk factor for 
development of ulcer bleeding (duodenal greater than gastric). Bleeding 
tends to occur after prolonged hospitalization and is most common in 
patients with severe co-morbidities. Such "nosocomial" gastrointestinal 
bleeding is associated with poor outcome. A study done by Terdiman JP 
et al showed that such patients had a mortality rate of 34%.11 It also 
showed that nosocomial ulcer bleeders were less likely to have a history 
of previous ulcer disease, to have H. pylori infection, or to be taking 
NSAIDs than those hospitalized for ulcer bleeding. 
Gastric Acid 
The evidence for a role of gastric acid in peptic ulceration is 
overwhelming and includes the hypersecretory disorder Zollinger-
Ellison syndrome, in which patients develop ulcers with high frequency. 
The ability of antacid therapy alone to heal upper gastroduodenal tract 
ulceration also supports the role of acid. However, controversy exists 
surrounding the role of acid in inducing bleeding in non-           
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Zollinger-Ellison ulceration. Perhaps the best evidence of a role for acid 
in acute upper gastrointestinal haemorrhages comes from data indicating 
that acid reduction by proton pump inhibitors in patients with active or 
recent bleeding from upper gastrointestinal ulcerative lesions reduces 
the risk of bleeding and rebleeding12-16. 
Helicobacter pylori 
         As with acid, the link between H. pylori and peptic ulceration is 
firm. However, the role of H. pylori in ulcer bleeding is controversial.  
Aspirin and Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) 
Aspirin and NSAIDs are probably the most important 
predisposing factors for ulcer bleeding. The mechanism of injury and 
ulceration is complex but appears to involve reduced production of 
cyclooxygenase-generated cytoprotective prostaglandins. Further, the 
risk of bleeding is increased by NSAIDs or aspirin, in part because of 
platelet dysfunction. The risk of gastrointestinal bleeding secondary to 
NSAIDs appears to be dose related. 
The evidence for an increased risk of NSAID-induced upper 
gastrointestinal bleeding is derived largely from case-control studies. 
Although the data from these studies are not entirely consistent, the 
following points appear to be reliable: (1) the risk for gastric ulceration 
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is greater than for duodenal ulceration, although both are increased;     
(2) the risk of bleeding varies with the individual NSAID; for example, 
the relative risk of bleeding is greatest with azapropazone and 
piroxicam, but less with ibuprofen; (3) the risk of bleeding is dose 
dependent; and (4) multiple cofactors contribute to NSAID risk. 
Cofactors important in NSAID-induced ulceration are diverse. For 
example, age and previous upper gastrointestinal bleeding appear to be 
important predictors of NSAID-associated bleeding. In a study by 
Silverstein et al17, it was found that age greater than 75 years, history of 
heart disease, history of peptic ulcer, and history of previous 
gastrointestinal bleeding were independent predictors of NSAID-
induced complications. These data are highly consistent with other data 
emphasizing the importance of age as an independent risk factor for 
NSAID ulceration. In addition, H. pylori may be a risk factor for ulcers, 
although the degree of risk is controversial.18,19  Finally, corticosteroids, 
the bisphosphonate alendronate, and ethanol appear to potentiate the 
ulcerogenic effect of NSAIDs and may predispose to UGIH. 
Ethanol 
The role of ethanol as a predisposing factor for ulcer-related acute 
upper gastrointestinal bleeding is difficult to assess. It is important to 
note that patients who ingest ethanol chronically may have alcohol 
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induced liver disease and secondary portal hypertension, which is an 
important risk factor for nonulcer upper gastrointestinal haemorrhages. 
Nonetheless, ethanol is well known to induce gastric mucosal injury, 
and thus may cause or potentiate ulcer bleeding. Deleterious effects of 
NSAIDs are further increased among drinkers20. 
Anticoagulation Therapy 
Anticoagulation increases the risk of bleeding from ulcer disease. 
The relative risk of hospitalization for bleeding ulcer in anticoagulated 
patients is about 3, and anticoagulants further increase the risk of 
bleeding in those taking NSAIDs23.  In a randomised control study done 
by Shorr RI  et al21, it was found that compared with subjects who took 
neither anticoagulants nor NSAIDs, the relative risk of hemorrhagic 
peptic ulcer disease among users of both drugs was 12.7 (95% 
confidence interval, 6.3 to 25.7). This data emphasizes the risk of 
anticoagulants, particularly for those who use NSAIDs. 
PROGNOSTIC FACTORS IN ULCER BLEEDING 
Most ulcer bleeds are self-limited, and in these patients recovery 
is uneventful. However, a subset of patients have continued or recurrent 
bleeding, which is associated with a poorer prognosis. The prognostic 
factors emphasized in upper gastrointestinal bleeding apply particularly 
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to bleeding ulcers since they comprise the majority of upper 
gastrointestinal bleeding lesions. The three most important factors are 
age, existing co-morbid conditions and the nature of type of lesion found 
at endoscopy. 
The seminal observation of Griffiths and colleagues that a visible 
vessel in an ulcer base was predictive of uncontrolled or recurrent 
bleeding established the importance of the endoscopic appearance of 
ulcers.22 The most critical endoscopic features in ulcer bleeding include 
the following stigmata of active/recent bleeding: active arterial spurting, 
oozing of blood, a visible vessel, and fresh or old blood clot. Visible 
vessels are described endoscopically as elevated, dark red or purple 
lesions that protrude from the ulcer crater. A number of studies have 
examined endoscopic features as predictors not only of rebleeding but 
also of outcomes.23         
Despite the difficulty in assessing stigmata of ulcer bleeding, it is 
accepted that certain characteristics of the ulcer at the time of endoscopy 
provide important prognostic information. For example, increasing ulcer 
size (>1cm) is associated with an increased rate of rebleeding and 
mortality24. Endoscopic haemostasis is less often successful in ulcers 
larger than 2 cm24. The appearance of the ulcer base is also important 
and may be one of the following: (1) a clean base only, (2) an ulcer base 
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with a flat, pigmented spot, (3) an ulcer base with an adherent clot,       
(4) an ulcer base with a visible vessel (also called a pigmented 
protuberance or sentinel clot that appears raised and rounded and is 
resistant to washing); or (5) an ulcer base containing a visible vessel or 
an adherent clot that is actively oozing or spurting. Although there is 
general consensus about management of patients with active bleeding, 
visible vessels, flat spots, and clean bases, controversy surrounds 
management of adherent clots, particularly after vigorous attempts to 
remove the clot. A prospective outcome study done by Laine et al25 
showed that vigorous irrigation was useful in this population and that 
endoscopic findings after washing may help triage endoscopic 
management at initial endoscopy. 
GASTRIC EROSIONS 
Although hemorrhagic and erosive gastritis refer to findings at 
endoscopy, a definite association between gastritis and significant 
bleeding has not been demonstrated.  However, gastritis, most often 
erosive, remains a time-honoured cause of upper gastrointestinal 
bleeding, reported by endoscopy to be the cause of bleeding in 16% of 
patients.26 Gastritis or erosive gastric injury rarely causes 
haemodynamically significant bleeding. When it does, patients usually 
have an underlying coagulopathy. 
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          Subepithelial erosions develop in the following clinical situations:           
(1) after ingestion of NSAIDs, (2) in stress-related medical illnesses, and          
(3) with ethanol. The most common of these is NSAID ingestion. Of 
patients who ingest NSAIDs chronically, 40% to 60% have erosions at 
any given time, and 15 to 30% have ulcers.  
Stress-related gastric mucosal injury occurs in extremely ill 
patients with serious trauma, extensive burns, major surgery, major 
medical illness (respiratory failure, sepsis, renal failure), and major 
neurologic trauma or intracranial disease. Indeed, some degree of stress-
related gastric injury can be found in virtually all patients admitted to 
the intensive care unit, prompting the widespread use of prophylactic 
regimens for these patients. 
Prophylaxis for stress-induced gastric injury in specific subsets of 
patients is warranted. Two strong independent risk factors for bleeding 
are respiratory failure and coagulopathy. Patients with respiratory failure 
on mechanical ventilation were studied in a randomized controlled trial 
by Cook D et al comparing ranitidine which sucralfate.27 Clinically 
significant gastrointestinal bleeding developed in 10 of 596 (1.7%) 
patients receiving ranitidine, compared with 23 of 604 (3.8%) of those 
receiving sucralfate (relative risk, 0.44; 95% CI, 0.21 to 0.92;P = 0.02). 
There was no difference in ventilator-associated pneumonia in the two 
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groups. These data suggest that routine prophylaxis is beneficial in this 
population. Whether ranitidine is superior or more cost effective 
compared with proton pump inhibitors is unknown. 
It is commonly believed that ethanol ingestion causes gastric 
erosions and gastrointestinal bleeding. However, support for this 
position is largely derived from experimental animal studies that infused 
extremely high concentrations of ethanol into the stomach. The term 
hemorrhagic gastritis is frequently applied to the subepithelial 
haemorrhages seen at endoscopy in alcoholic patients. However, 
histologic extravasation in such patients is typically superficial, and 
concomitant mucosal oedema is a prominent feature in adjacent, 
nonhaemorrhagic mucosa. 
          Alcohol consumption is a risk factor for upper gastrointestinal 
haemorrhage only in those with excessive ethanol consumption (4 or 
more drinks per day)43. An endoscopic study by Wilcox CM et al in 
alcoholics found that upper gastrointestinal haemorrhage in most of 
these patients was the result of peptic ulcer disease or disorders related 
to portal hypertension.44  
Endoscopic therapy is generally not useful for treatment of 
gastritis of any etiology, although it can be attempted if a small number 
of isolated erosions appear to be the source of bleeding. Selective 
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arterial infusion of vasopressin has been reported to stop bleeding in 
patients with gastritis,28 but its use requires considerable expertise, and it 
has not been rigorously studied.  
DUODENITIS  
Although duodenitis is often included in differential diagnosis of 
upper gastrointestinal haemorrhage, it is a rare cause of acute bleeding. 
Risk factors for severe erosive duodenitis are similar to those found in 
patients with bleeding peptic ulcers, like NSAIDs and H. pylori, and 
often is associated with anticoagulation therapy. The bleeding is usually 
self-limited and rarely requires intervention. 
MALIGNANCY  
Neoplasms of the oesophagus, stomach, and upper small intestine 
cause acute upper gastrointestinal haemorrhage infrequently. The 
majority of tumours associated with clinically significant acute UGIH 
are malignant45. Of the many tumours that cause UGIH, the most 
common is advanced gastric adenocarcinoma45. A small proportion of 
bleeding lesions have been managed with injection or coagulation 
therapy, and bleeding polypoid lesions can sometimes be snared, but 
large and/or sessile bleeding lesions typically require surgical 
intervention. These patients with upper gastrointestinal bleeding from 
tumours have a 1-year survival rate of 11%. 
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DIEULAFOY'S LESION 
Dieulafoy's lesion, also termed exulceratio simplex Dieulafoy, 
refers to an abnormally large artery that retains the large calibre of its 
feeding vessel as it approaches the mucosa. This large vessel is thought 
to compress the mucosa and cause a small erosion with rupture of the 
vessel into the lumen. Dieulafoy's lesions are not uncommon, 
accounting for up to 6% of cases of upper gastrointestinal hemorrhage47. 
Dieulafoy's lesions are typically found in the proximal portion of the 
stomach, usually within 6 cm of the gastroesophageal junction, but they 
may be located anywhere in the gastrointestinal tract. 
Bleeding is often massive and recurrent; it is often difficult to 
identify the lesion, unless it is actively bleeding or is associated 
endoscopically with stigmata of recent bleeding. Endosonography may 
be useful in the detection of Dieulafoy’s disease in patients with 
unexplained upper gastrointestinal bleeding47. Therapy with injection 
techniques, coagulative therapy, haemoclips, and banding can all control 
bleeding and prevent rebleeding in over 95% of cases. The long-term 
prognosis of patients with Dieulafoy's lesions, in the absence of 
concomitant medical illness, is excellent. 
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VASCULAR LESIONS  
Vascular Ectasia 
Vascular lesions are an uncommon, but important, cause of upper 
gastrointestinal tract bleeding. A number of vascular disorders can cause 
upper gastrointestinal haemorrhages, but the most common vascular 
lesions are vascular ectasias, which are most often found in the stomach 
or duodenum. Vascular ectasias more commonly cause lower 
gastrointestinal and occult bleeding than upper gastrointestinal tract 
bleeding. They are found in a variety of conditions, including renal 
failure, cirrhosis, scleroderma, the CREST syndrome, radiation injury, 
collagen diseases such as pseudoxanthoma elasticum and Ehlers-Danlos 
syndrome, and von Willebrand's disease. Vascular ectasias appear to be 
most often associated with chronic renal failure. The prevalence of 
vascular ectasia as a cause of upper gastrointestinal bleeding is related to 
the duration of renal failure and the requirement for hemodialysis. 
The treatment of vascular ectasias is difficult because they are 
rarely found in isolation. Patients with lesions that are readily identified 
or are actively bleeding are best treated endoscopically with laser, 
bipolar electrocoagulation, banding, injection therapy, or argon plasma 
coagulation; each technique appears to be effective and safe in this 
setting. Perforation of the gastrointestinal tract, however, is a risk, 
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particularly with electrocoagulation or laser therapy. Massive bleeding 
may be stopped by angiographic therapy. Recurrent bleeding from a 
specific bleeding lesion after endoscopic or angiographic therapy is 
uncommon; surgical therapy is reserved for low-risk patients who have 
lesions that are clearly identified as the bleeding source.  
Arteriovenous Malformations 
True arteriovenous malformations, which may appear as raised or 
nodular lesions at endoscopy, are rare. These lesions are probably 
congenital in origin and, in contrast to vascular ectasias, usually involve 
the submucosa; they may be large and involve any portion of the gut 
wall; the primary treatment is resection of the involved bowel. 
Hereditary Haemorrhagic Telangiectasia  
Hereditary haemorrhagic telangiectasia is an autosomal dominant 
disorder characterized by telangiectasias of the skin, mucous 
membranes, and gastrointestinal tract. The peak incidence of bleeding is 
in the 6th decade of life, and can originate from any site in the 
gastrointestinal tract.  Lack of telangiectasias on the lips, oral and 
nasopharyngeal membranes, tongue, and periungual areas should cast 
doubt on the diagnosis. Of many forms of treatment, endoscopic therapy 
is most effective in stopping haemorrhage from actively bleeding 
lesions. Surgical therapy is reserved for those with discrete lesions 
30 
 
identified as the source of the bleeding. Hormonal therapy, typically 
with an oestrogen and progesterone combination, has met with mixed 
results. 
Haemangioma 
Haemangiomas causing upper gastrointestinal haemorrhage are 
most commonly identified in the upper small intestine. These benign 
vascular tumours made up of proliferating vessels, almost all of which 
are cavernous haemangiomas, appear as single or multiple red, purple, 
or blue nodular lesions. These lesions generally should not be treated 
endoscopically. Angiographic therapy may stop bleeding; however, the 
most effective treatment is surgical. 
Gastric Vascular Ectasia 
Gastric vascular ectasia constitutes a group of recently recognized 
entities that rarely cause acute upper gastrointestinal haemorrhage. This 
lesion is characterized by aggregates of red spots. When the aggregates 
are arranged in a linear pattern in the antrum of the stomach, the term 
gastric antral vascular ectasia (GAVE), or watermelon stomach, is used. 
Its pathogenesis is unknown. Although originally thought to be portal 
hypertensive in etiology, recent work casts doubt on this hypothesis. 
Neither use of beta-blockers nor standard portal decompression has 
proved effective for treatment of gastric vascular ectasia, nor has 
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endoscopic thermal therapy or antrectomy been effective. One small 
trial, ethinyl estradiol (30 µ g) and norethisterone (1.5 mg) daily led to a 
significant decrease in transfusion requirements in the majority of 
patients29; however, these results have not been confirmed. 
PROGNOSIS IN NVUGIH 
Many studies have addressed the factors that predict outcome in 
patients with upper gastrointestinal hemorrhage.30-34 Because upper 
gastrointestinal bleeding is most commonly caused by ulceration, 
prognostic factors for it tend to reflect those for bleeding peptic ulcer. 
Approximately 80% of upper gastrointestinal bleeding episodes are self-
limited and require only supportive therapy.35 The two most important 
prognostic variables appear to be the cause of bleeding and the presence 
of underlying comorbidity.  
The major factors that determine the prognosis, course, and the 
outcome are 
1. Age  
2. Presence/Absence of Comorbid Conditions 
3. Endoscopic Diagnosis 
4. Presence of Stigmata of Bleeding on Endoscopy 
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       Several scoring systems have been designed to identify patients 
with a high risk of adverse outcomes; the measures have generally been 
ascertained from mathematical models of risk of death or rebleeding. 
ROCKALL SCORE 
In 1996,a  prospective study done by T A Rockall et al36 on 
patients admitted with UGIH, attempted to identify patients who had 
negligible risk of further bleeding or death and for whom early discharge 
or even out patient management would be possible. It was also intended 
to identify patients with a high risk of adverse prognosis and thereby 
subject them to more intense monitoring. 
In this study by, a prospective audit of the management and 
outcome of 4201 patients from 74 hospitals in four health regions in the 
UK were identified over a 4-month period during 1993. The participants 
for this analysis consisted of 2531 patients who were admitted as acute 
emergencies with acute upper gastrointestinal bleeding. A numerical 
scoring was devised based on three clinical variables and two 
endoscopic variables. 
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The clinical variables were:  
A.  Age (score 0 – 2),  
B.  Presence/absence of shock (score 0 – 2) and  
C.  Presence/absence of co-morbid conditions (score 2 – 3) 
The two endoscopic variables included 
A.  Endoscopic diagnosis (0 – 2) and 
B. Presence or absence of stigmata of recent bleed (0 and 2). 
The maximal possible score was 11. 
The patients’ scores were correlated with the event of rebleeding, 
mortality and the duration of hospital stay.  The results showed that the 
score identified a large proportion of patients with a low risk of further 
bleeding or death. It was also found that the length of the hospital stay 
also increased with increasing score. 
In our study the usefulness of the Rockall score as a prognostic 
score analysed. Its correlation with the event of rebleed, transfusion 
requirements, duration of hospitalisation and the final outcome is 
studied. 
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                   MATERIALS AND METHODS 
SETTING 
The study was conducted on patients admitted in the wards of the  
Institute of Internal Medicine, Madras Medical College and Government    
General Hospital, Chennai. 
COLLABORATING DEPARTMENTS 
Institute of Internal Medicine, Government General Hospital 
Department of Medical Gastroenterology, Government General        
Hospital 
ETHICAL APPROVAL 
      Obtained              
STUDY DESIGN 
Single centre, non-interventional, comparative prospective study. 
STUDY PERIOD 
    January 2008 to September 2008 
SAMPLE SIZE 
76 patients 
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SELECTION OF STUDY SUBJECTS 
Inclusion Criteria 
 Patients admitted in the general medical wards for Upper 
Gastrointestinal bleeding in whom endoscopy reveals a non-
variceal cause for the bleeding.       
 Patients of age greater than 12 years from both the sexes were  
 included in the study. 
  Exclusion Criteria 
• In-patients who were admitted for a problem other than a Gastro-
intestinal bleed who develop UGI bleed during hospital stay. 
• Out-patients who undergo endoscopy for Upper Gastrointestinal 
bleed. 
• Patients admitted with Upper Gastrointestinal bleeding who do 
not undergo endoscopy. 
CONSENT 
The study was carried out with the informed written consent of 
each of the participants. 
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METHODOLOGY 
Patients with Upper Gastrointestinal bleeding in whom endoscopy 
shows a non- variceal etiology for the bleed, are included in the study. 
The findings at endoscopy, the lesion and the presence or absence of 
stigmata of recent bleeding are noted. Data are collected from these 
patients regarding the nature and duration of their symptoms, co-morbid 
medical illnesses, history regarding NSAID use, past history of Upper 
Gastrointestinal bleeding, their alcohol and smoking habits. Their 
clinical examination findings, pulse rate, blood pressure, and the 
presence/absence of abdominal tenderness noted at the time of 
admission are collected from their medical case record. Relevant 
laboratory data like haemoglobin, urea, creatinine and tests for liver 
function are also noted.     
          A numerical score – Rockall score is calculated based on the 
clinical findings at presentation and their endoscopy findings. Three 
clinical variables are analysed, namely, 
A.  Age (score of 0-2),  
B.  Presence of Shock (0-2),  
C.  Co morbid conditions (2-3)  
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The two endoscopic variables included in the scoring are   
A.  The endoscopic diagnosis (0 – 2) and  
B.  Presence of stigmata of recent haemorrhage (0 and 2).  
The Rockall score is obtained by the sum of the individual scores 
for the variables analysed. Based on the score the patients are stratified 
as 
A. Low risk (score ≤2),  
B. Intermediate risk (3 – 5) and 
C. High risk (≥6).  
The Rockall score is correlated with the 1) occurrence of            
re-bleeding or prolonged bleeding, 2) the duration of hospitalisation, 3) 
requirement of transfusions and  4)  the final outcome.  
These data are collected on the tenth day after the initial 
presentation, either by a direct interview or by a telephonic interview in 
the event of the patient being discharged before the tenth day.  
The data collected are analysed statistically for correlation with 
the Rockall score. Microsoft Windows’ Excel was used to tabulate the 
data and SPSS – Statistical Package for Social Sciences was used to 
analyse the data. 
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THE ROCKALL SCORING SYSTEM 
 
 
 
 
SCORE  
VARIABLE 
0 1 2 3 
 
AGE 
 
<60 
  
60-79 
 
≥80 
 
- 
 
SHOCK       
(SBP mmHg, 
HR- beats/min) 
 
‘No 
shock’: 
SBP≥100 
and 
HR<100 
 
‘Tachycardia’: 
SBP≥100 and 
HR≥100 
 
‘Hypotension’: 
SBP<100 
 
 
- 
 
COMORBIDITY 
 
No major 
morbidity 
 
- 
Cardiac 
failure, 
ischemic heart 
disease any 
major 
comorbidity 
Renal 
failure, liver 
failure, 
disseminated 
malignancy 
 
DIAGNOSIS 
Mallory-
Weiss tear, 
no lesion 
identified 
and no 
SRH/blood
 
All other 
diagnosis 
 
Malignancy of 
the upper GI 
tract 
 
- 
 
MAJOR SRH 
None or 
dark spot 
only 
 
- 
Blood in upper 
GIT, adherent 
clot, visible or 
spurting vessel 
 
- 
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D E F I N I T I O N S 
UPPER GASTROINTESTINAL HAEMORRHAGE     
Haematemesis or melaena or other firm clinical or laboratory 
evidence suggesting a site of bleeding in the gastrointestinal tract 
proximal to the ligament of Treitz. 
HAEMATEMESIS 
It is defined as the vomiting of blood or blood clots and indicating 
an upper gastrointestinal site of the bleeding. 
MELAENA 
Melaena is defined as the passage of black, tarry and offensively 
foul-smelling stools. 
HAEMATOCHEZIA 
Haematochezia is defined as the passage of bright red blood from 
the rectum which may or may not be mixed with stool. 
REBLEEDING 
In this study, rebleeding was defined as a new episode of bleeding 
within the first ten days after the initial presentation, which manifested 
as recurrent haematemesis, haematochezia, fresh blood in the naso-
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gastric aspirate, or circulatory instability occurring after initial 
hemodynamic stabilisation. Melaena if continuing even after the fourth 
day after first day of melaena is taken as ‘continuing’ bleed; and for 
analytical purposes in this study is grouped under ‘Rebleed’. 
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RESULTS 
 
AGE DISTRIBUTION 
The study population comprised of 76 patients. Their age ranged 
from 14 years to 80 years. The mean age of the group was 44.14years 
(±14.9). 
 
Chart 2: Age Distribution of patients with NVUGIH 
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AGE AND DURATION OF HOSPITALISATION 
The average duration of hospital stay in the study population was 
5.72 days. The duration of hospitalisation increased with the age of the 
patient. It was longest (6.3 days) for those >50 and shortest (5.2days) for 
those ≤30 years. 
Table 1: Age and duration of hospitalisation 
 
 
AGE AND INCIDENCE OF REBLEED 
The incidence of re-bleed in this study was found to increase with 
increasing age, as is evident from the following data. 
Table 2: Age and incidence of re-bleed 
 
AGE GROUP (years) DURATION OF HOSPITALISATION  (days) 
≤30 5.29 
31-50 5.41 
>50 6.37 
Total Mean 5.72 
AGE GROUP (YEARS) REBLEED 
<30 29% 
30-50 37% 
>50 55% 
AVERAGE 42% 
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AGE AND DIAGNOSIS 
The average age of the patients against each diagnosis was the 
highest in patients with malignancy (58.14 yrs) while it was the least in 
patients with mucosal erosions (39.12). The average age of patients with 
PUD was 45.37 yrs.        
 
Table 3: Endoscopic diagnosis and the average age 
DIAGNOSIS AVG. AGE IN YEARS 
CA 58.14 
MW 45.67 
PUD 45.37 
Normal Study 41.67 
Mucosal Erosions 39.21 
Grand Total 44.14 
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SEX DISTRIBUTION 
Males constituted 77.63% of the study population and females 
22.53 percent. The mean age of the female population in the study group 
was 38.23 years and that of males was 45.84 years. The most common 
diagnosis at endoscopy in females was Erosive Mucosal disease 
constituting 58.8% of the total diagnosis in females while in males the 
most common diagnosis was Peptic Ulcer disease accounting for 48.8% 
of the diagnosis.  
Table 4: Sex and age distribution 
 A G E 
Sex ≤30yrs 31-50 yrs >50 yrs Grand Total 
F 8 5 4 17 
M 9 27 23 59 
Total 17 32 27 76 
Chart 3: Sex and age distribution 
 
AGE 
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SYMPTOM ANALYSIS  
In this study 96% presented with haematemesis and 72% with 
melaena. Retching was present in 27.6% of the entire study population 
and all patients with Mallory Weiss tear had a positive history. Forty 
seven percent of the population had abdominal pain. Abdominal pain 
was more common in patients with malignancy than in patients with 
Peptic Ulcer Disease.  
 
                             Table 5: Symptom Analysis 
 
 
 
 
DIAGNOSIS 
 
HAEMATEMESIS 
% 
 
MELAENA 
% 
 
HAEMATOCHEZIA 
% 
 
ABDOMINAL 
PAIN% 
 
RETCHIN
% 
PUD 100 88 0 42 34 
CA 100 100 0 85 29 
ME 89 46 0.3 39 10 
MW 100 100 0 100 100 
TOTAL 96 72 0.01 47 27.6 
46 
 
 
 
 
 
Chart 4: Symptom Analysis of patients with NVUGIH 
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ALCOHOL INTAKE 
 
In this study population alcohol consumption was restricted to the 
males. Seventy one percent of the males had history of alcohol 
consumption on the day or the day before the day of presentation of the 
bleeding. History of alcohol intake was present in 70.3% of the males 
with PUD, in 66.7% of patient with Mucosal erosive disease and in 
100% of patients with Mallory Weiss tear. 
 
 
Chart 5: Alcohol Intake in males and diagnosis 
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SMOKING 
 
Smoking was restricted to the males in the study population. 
Fiftyeight percent of the males with UGI bleed were smokers. Eighty six 
percent of the patients with UGI malignancy, 55.5% of male patients 
with PUD and 44.4% of patients with Mucosal Erosive lesions were 
smokers.  
 
 
Chart 6: Smoking and Etiology of bleed 
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NSAID INTAKE 
NSAID intake was associated in 30.26% of the patients. NSAID 
intake was relatively more common in females than in men. A positive 
history was present in 25% of the male patients and in 47% of the 
female patients. In patients with Gastric ulcer and Duodenal ulcer a 
positive drug history for NSAIDS was present in 40% and 37% 
respectively while in patients with erosive mucosal disease, 32% gave a 
positive history. Ref Chart 7 
Chart 7: NSAID intake and diagnosis 
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PAST HISTORY OF UGIH 
 
Out of the seventy six patients in the study, 24(31.6%) had a past 
history of UGI bleed. Patients with PUD had the highest past incidence 
of UGI bleed (42.4%) and patients with gastric carcinoma (CA) had the 
least (14%).    
 
 
 
Chart 8: Etiology of Bleed and past history of Bleed 
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 DIAGNOSIS 
At endoscopy the most common diagnosis was PUD (46%), 
followed by Mucosal erosions (36.8%) followed by GI malignancy 
(9%). Among the patients with PUD the most common lesion was 
gastric ulcer (19.7%) and 10.5% had both gastric and duodenal ulcers. 
Three patients had a normal study at endoscopy. Ref Chart 9  
Table 6: Etiology of bleed – Distribution 
ENDOSCOPIC 
DIAGNOSIS TOTAL PERCENTAGE 
DU 
GU 
GU+DU 
OU+GU 
OU 
Mucosal Erosions 
Mallory Weiss 
Normal Study  
Gastric Malignancy 
8 
15 
8 
2 
2 
28 
3 
3 
7 
10.50% 
19.70% 
10.50% 
2.60% 
2.60% 
36.80% 
3.90% 
3.90% 
9.00% 
Grand Total 76 100% 
 
Chart 9: Endoscopic diagnosis – Distribution 
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DIAGNOSIS AND REBLEED 
In this study population, 42% of the patients had rebleeding. The 
rebleeding incidence was lowest for the patients with a normal study at 
endoscopy and highest for the patients with GI malignancy and those 
patients with Mallory-Weiss tear. Ref. Chart 10 
Table 7: Endoscopic Diagnosis and Re-bleed 
 
 
 
 
 
 
Chart 10: Diagnosis and Re-bleed 
ENDOSCOPIC DIAGNOSIS 
REBLEED 
PERCENTAGE 
NORMAL STUDY  0% 
MUCOSAL INFLAMMATION 10.70% 
OU 50% 
GU 40% 
OU+GU 50% 
GU+DU 62.50% 
DU 75% 
MALLORY-WEISS 100% 
GASTRIC CA 100% 
ALL 42% 
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DIAGNOSIS AND DURATION OF HOSPITALISATION  
The average duration of hospitalisation was 5.72 days. The 
longest in-hospital stay period (in-medical ward stay in case of 
malignancy) was for patients with gastric carcinoma whereas patients 
with a normal study at endoscopy had the shortest hospital stay. Ref. 
Chart 11 
Table 8: Diagnosis and duration of Hospitalisation 
DIAGNOSIS 
DURATION OF HOSPITALISATION 
(days) 
Gastric CA 7.14 
PUD 6.23 
Mallory Weiss 6.33 
Mucosal Erosions 4.86 
Normal Study 4 
TOTAL 5.72 
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Chart 11: Diagnosis and Duration of Hospitalisation 
 
 
 
DIAGNOSIS AND TRANSFUSION REQUIREMENTS 
Sixty two percent of the patients required blood transfusion. 
Patients with Gastric Carcinoma required the highest no of 
transfusions.The average number of units transfused in this study is 
1.04.   Ref. Chart 12 
Table 9: Diagnosis and Transfusion Requirements 
DIAGNOSIS 
AVG. NO. OF UNITS 
TRANSFUSED 
Gastric Carcinoma 1.86 
PUD 1.34 
Mallory Weiss 1.66 
Mucosal Erosions 0.5 
Normal Study 0 
TOTAL 1.04 
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Chart 12: Diagnosis and Transfusion requirements 
 
 
 
 
OUTCOME 
In this study 86.8% of the study population improved and were 
discharged. Five patients required endoscopic intervention constituting 
8% of the patients in the ‘improved’ group. Eight patients (10.5%) were 
taken up for surgical management. All these patients had gastric 
carcinoma. There was one death, accounting for 1.3% of the population. 
Ref. Chart 13 
Table 10: Outcome of the patients 
OUTCOME PERCENTAGE 
Improved 86.80% 
Refered 10.50% 
Expired 1.30% 
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Grand Total 100% 
    
Chart 13: Outcome of the patients 
 
              
ROCKALL SCORE 
Rockall score was calculated for each patient in the study 
population. The majority of patients had a low Rockall score. Patients 
with a high Rockall score of >5 constituted only 2.6% of the study 
population. The average Rockall score of the study population was 2.63.  
Ref. Chart 14. 
Table 11: Distribution of patients over Rockall score 
ROCKALL 
SCORE NO OF PATIENTS PERCENTAGE 
≤2 44 57.90% 
3 to 5 30 39.50% 
>5 2 2.60% 
OUTCOM
57 
 
Grand Total 76 100% 
 
 
 
Chart 14: Distribution of patients over Rockall score 
 
 
ROCKALL SCORE AND THE EVENT OF REBLEED 
The value of Rockall score was correlated with the event of the 
patient having a rebleed. It was found that as the score increased there 
was a greater percentage of patients rebleeding. The correlation was 
highly significant with a p value of 0.000001. Ref. Chart 15. 
Table 12: Rockall Score and correlation with re-bleed 
ROCKALL SCORE REBLEED 
≤2 3-5 >5 
TOTAL 
YES 6.8% (3) 90.0% (27) 100% (2) 42.1% 
NO 93.2% (41) 10.0% (3) 0% 57.9% 
Rockall 
Score 
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TOTAL 57.9% (44) 39.5% (30) 2.6% (2) 100% 
p value < 0.000001 
 
Chart 15: Rockall Score and incidence of re-bleed 
 
ROCKALL SCORE AND DURATION OF HOSPITALISATION 
It was found in this study that there was a direct proportional 
relation between the value of the Rockall score and the duration of 
hospital stay of the patients. There was a positive correlation between 
the two with a highly significant p value of 0.000001. Ref. Chart 16 
Table 13: Rockall score and correlation with duration of Hospitalisation 
ROCKALL SCORE  HOSPITAL STAY 
≤2 3 to 5 >5 
TOTAL 
≤3 13.6% (6)  0%  0%   7.9% (6) 
4-6 days  84.1% (37)  33.3% (10)  0%  61.8% (47) 
>6  2.3% (1)  66.7% (20)  100% (2) 30.3%(23) 
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TOTAL 57.9% (44) 39.5% (30) 2.6% (2) 100% (76) 
 p value< 0.000001 
 
Chart 16: Rockall score and duration of Hospitalisation 
 
      
ROCKALL SCORE AND TRANSFUSIONS 
There was an increasing need for transfusing the patients with 
increasing Rockall score. The average quantity of blood transfused for 
the patients in the study was 1.03 units. Ref. Chart 17 
 
 
 
 
Table14:  Rockall Score and correlation with transfusion requirements 
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Chart 17: Rockall score and transfusion requirements 
 
ROCKALL SCORE AND DIAGNOSIS 
In this study, the average Rockall score was 2.63. Patients with GI 
malignancy had the highest Rockall score of 4.14, followed by PUD. 
Patients with a normal study at endoscopy had the least Rockall Score of 
0.66. Ref. Chart 18 
Table 15: Diagnosis and the Mean Rockall Score 
Diagnosis Avg. Rockall Score 
CA 4.14 
PUD 3.34 
MW 3 
ME 1.53 
NORMAL STUDY 0.66 
ROCKALL SCORE 
Average of No. of units 
transfused 
≤2 0.432 
3 to 5 1.87 
>5 2 
Mean transfusion 
req. 1.03 
p value – 0.0001 
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Total Avg. score 2.63 
 
 
Chart 18: Diagnosis and the mean Rockall Score 
 
 
 
 
 
 
 
 
 
ROCKALL SCORE AND HAEMOGLOBIN 
Rockall score also reflected the Haemoglobin levels of the 
patients in the study. It was found that with as the haemoglobin level 
decreased the Rockall score increased. It had a significant inversely 
correlation with a p value of 0.003. Ref. Chart. 19 
Table 16: Hemoglobin and Rockall Score 
 
HAEMOGLOBIN AVG. ROCKALL SCORE 
<8 3.08 
8 to 12 2.72 
>12 1.66 
Grand Total 2.63 
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p  value – 0.003 
 
Chart 19: Haemoglobin and the Average Rockall Score 
 
 
ROCKALL SCORE AND UREA 
In this study it was found that patients with a high Rockall score 
also had elevated urea levels. The positive correlation was highly 
significant with a p value of 0.0001.  Ref. Chart 20 
Table 17: Rockall score and correlation with Urea value 
U   R   E   A     
Rockall 
Score <25 25 to 40 41 to 55 >55 
Grand 
Total 
≤2 47%(21) 36%(16) 5%(2) 11%(5) 100%(44) 
3 to 5 10%(3) 10%(3) 40%(12) 40%(12) 100%(30) 
>5   50%(1) 50%(1) 10%(2) 
Grand Total 24 19 15 18 76 
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P value = 0.0001 
 
 
Chart 20:Rockall Score and Urea levels 
 
 
ROCKALL SCORE AND OUTCOME 
The Rockall score of the patient who expired was 4. The average  
Rockall score of the patients who were referred to surgery was 3.87. The 
average Rockall score was the least (2.47) in the patients who had 
improved and were subsequently discharged..Ref. Chart 21 
Table 18: Outcome and Mean Rockall score 
OUTCOME AVG. ROCKALL SCORE 
Improved 2.47 
Referred To Surgery 3.875 
Expired 4 
All 2.63 
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Chart 21: Final Outcome and Mean Rockall Score 
  
 
DISCUSSION 
Non-variceal upper gastrointestinal haemorrhage is a common 
medical emergency in everyday clinical practice. It can present with a 
varied clinical spectrum ranging from the insignificant to the 
catastrophic. Hence it is imperative that these patients need to be 
stratified according to their risks into those who are likely to have a 
complication (rebleed, mortality) and those in whom a less dramatic 
outcome is expected. This not only serves as a tool in better 
management of the former group but can also cut in-hospital costs of the 
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latter. Several adverse prognostic variables are known to affect the 
outcome. This study attempts to analyse these variables and the clinical 
profile of the patients admitted with NVUGIH. It also attempts to 
correlate the outcome with a prognostic scoring system - The Rockall 
Score. 
AGE DISTRIBUTION  
Age is an independent adverse prognostic variable in patients with 
NVUGIH38. In this study the mean age was 44.14 years (±14.9) as 
compared to 67.17±16.7 years reported by Marco Soncini37 et al, in a 
study done in Italian population. The study-population of  Vreeberg EM 
et al had a mean age of 71 years34. In our study, the majority of the 
population was middle aged (30-60years) and there was a trend of 
increasing duration of hospital stay with increasing age. The study also 
showed a greater incidence of rebleed with increasing age. 
Out of the 76 patients who formed the study population only one 
patient was ≥80 years. The Rockall score stratifies the age into age <60, 
60-79 and age ≥80. In this study the majority of patients fell into the first 
group with hardly any patients in the third group. This might be because 
the average life expectancy in Indian population is 62.8 years52 as 
compared to western population who have a higher life expectancy [75.2 
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years in the U.K.]. Hence in the Indian scenario it might be appropriate 
to scale down the age groups to ones appropriate to our population. 
SEX DISTRIBUTION 
Gastrointestinal bleeding is more common in the males1,2. Males 
constituted 77.63% of the study population. This could probably be 
attributed to the fact that in the Indian setting men expose themselves 
more commonly to ethanol and smoking as compared to women. 
Though in this study both alcohol intake and smoking was restricted 
only to men, women had a higher incidence of NSAID intake compared 
to men. The most common diagnosis at endoscopy was PUD in the 
males. Both Mallory-Weiss tear and gastric malignancy were restricted 
to males. It is well known that both PUD and gastric carcinoma are more 
common in men39.  The occurrence of Mallory Weiss tear only in males 
is partially explained by the fact that alcohol intake, a well known risk 
factor for its development38, was restricted to the males, though there are 
reservations, owing to the small sample size. The most common 
diagnosis in females was mucosal erosive disease. 
CLINICAL PRESENTATION 
In this study, abdominal pain, thought to be a classical feature in 
PUD, was present only in 42% of the patients with PUD. Endoscopic 
studies have shown that peptic ulcerations are often asymptomatic and 
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in one such study duodenal acid perfusion produced pain in only 38% of 
the individuals40. Pain was more common among patients with gastric 
carcinoma occurring in 85% of these patients. Retching was present in 
all three of the patients with diagnosis of MW tear. 
          Out of the 76 patients, based on the presentation, a definitive 
clinical etiological diagnosis could be made in only 63 patients; and 
among these patients the endoscopic diagnosis concurred with the 
clinical diagnosis in only 56% of the patients. It can thus be inferred that 
reliance on purely signs and symptoms is neither sensitive nor specific 
means to arrive at the etiological diagnosis. It is therefore imperative 
that patients with significant NVUGIH undergo endoscopic to ascertain 
the etiology as well as for the management if then indicated. 
 
DIAGNOSIS 
Peptic Ulcer Disease   :   PUD has been reported by Skok P et al. to 
account for nearly 50% of the cases with UGIB48. In our study PUD 
accounted for nearly half the cases diagnosed at endoscopy. The most 
common single lesion in this group was gastric ulcer (45% of PUD) 
followed by duodenal ulcer. There were a considerable proportion of 
patients with combined lesions (30% of PUD).   
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There is a greater risk of gastric ulceration as compared to 
duodenal ulcers with NSAIDS38. In this study NSAID intake was 
associated with 40% of the patients with gastric ulcers as compared to 
37% of patients with duodenal ulcer. 
Incidence of bleeding from DU is approximately twice that of 
gastric ulcers.38 Though in this study GU was commoner than DU, 
rebleeding was more common in patients with DU (75%) compared to 
GU (40%). The actual incidence of patients with gastric and duodenal 
ulcer who develop UGIB cannot be commented upon with this study. 
The duration of hospitalisation was also higher in patients with 
DU patients requiring on an average 7.6 days of hospitalisation as 
compared to 5.6 days for the patients with GU. The number of 
transfusions required was slightly more for DU (avg. 1.8 units) 
compared to GU (1.3 units). 
Table 19: Comparison between Gastric Ulcer and Duodenal Ulcer 
 Gastric Ulcer Duodenal Ulcer 
Re-bleed 40% 75% 
Avg. duration of hospitalisation 5.6 days 7.6 days 
Avg. no. of transfusions 1.3 days 1.8 units 
              
From this study it can be concluded that in a PUD patient with 
UGIB, DU has a more protracted course than a patient with GU.  
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MUCOSAL EROSIVE DISEASE  
In this study isolated mucosal erosion were detected in 36.8% of 
the study group as compared to 11% reported by TA Rockall et al41. The 
three known risk factors for mucosal erosions are alcohol, stress and 
NSAIDS44. In this study there was a history of alcohol intake in 42% of 
the patients. Thirty two percent of the patients had a history of NSAID 
intake. A much lower incidence of 61% was reported by Marco Soncini 
for drug induced UGIB37.  Stress an ill-defined abstract risk factor was 
not assessed in this study. 
The incidence of rebleeding was 10.7% much less compared to 
those with PUD. The average duration of hospitalisation was 4.86 days 
and the average no of units of blood that needed to be transfused was 
0.5.  Clearly the clinical course was more benign compared to those with 
PUD. 
GASTRIC CARCINOMA 
Gastric Ca accounted for 9% of the patients presenting with 
NVUGIH in this study. The incidence is quite high compared to the 4% 
reported by TA Rockall et al41. It could be explained by the fact that 
many of the patients in this group were initially under the diagnosis of 
PUD but later re-allotted to the CA group after the biopsy taken on 
suspicion during endoscopy confirmed malignancy. Adenocarcinoma 
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was reported in all their biopsies. After the biopsy report these patients 
were subsequently referred to surgical units for further management. 
Since there was at least some delay between the time of endoscopy and 
the time of arrival of the biopsy report after which they were referred, 
their duration of stay might not be exactly indicative of their actual 
requirement. Moreover these patients were not followed up in their 
respective surgical wards after transfer. Nevertheless these patients had 
the highest requirements for transfusions and the highest incidence of 
rebleed in the entire study group. 
MALLORY WEISS TEAR 
According to literature, they account for approximately 5% of 
cases of UGIH42. In our study it accounted for 4% of the total group. All 
of them had a contributory alcohol history and all gave a history of 
retching. In our study all three patients had rebled and were transfused. 
Since this group was small, no generalisations are attempted made based 
on this study. 
Three patients in the study had a normal UGI endoscopy. It is 
possible that these patients actually presented with haemoptysis and not 
haematemesis. Distinction between these two distinct symptoms is often 
blurred to patients. It is not uncommon to face a patient who is sure only 
of the fact that the portal of exsanguination was his mouth but can 
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contribute nothing more. Their inebriated state (two out of three in our 
study) only makes their history less clear and less reliable. However on a 
less accusative note, these patients might just have had a lesion (e.g. a 
Dieulafoy lesion) that was missed during endoscopy. 
OUTCOME 
The mortality rate for patients with UGIH in most studies was 
between 8% and 10%1,42. In this study the mortality rate was only 1.3%. 
There is a high possibility of underestimation of the mortality rate in our 
study since patients who died even before endoscopy, are not taken into 
consideration. The fact that an arbitrary cut of period (10 days) was 
chosen as the endpoint to record the outcome, would have also 
contributed to the low estimate, since delayed deaths (>10 days) due to 
rebleeding are not accounted for. 
 
ROCKALL SCORE 
The mean Rockall score of the entire population was 2.63± 1.72. 
The study by Marco Soncini et al had a mean Rockall score of 4.6±2.237 
and that by Robert A Enns had a mean score of 4.8±1.949.In our study, 
the low risk group formed the greater part of the population and the high 
risk group constituted just 2.6%. This is because moribund patients 
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(potentially “high risk”) who either died or were taken against medical 
advice before endoscopy, were not included in the study population. On 
the same lines, the fact that most endoscopies were done the morning 
after the presentation and not on an emergency basis could have 
contributed to the same effect.  
 
Table 20: Comparison of Rockall Scores among studies 
 
 
 
RE-BLEED 
Using the Chi square test, it was found that the Rockall score had 
a positive correlation with the event of rebleed. The correlation was 
highly significant with a p value of 0.000001. Just 6.8% of the patients 
with a low score rebleed. Rockall score can be used to reliably predict 
 Present 
Study 
Robert A Enns’ 
study 
Morco Soncini et 
al study 
Mean Rockall 
score 
2.63±1.72 4.8±1.9 4.6±2.2 
Low risk 57.9% 13% 17.8% 
Intermediate risk 39.5% 53% 48.7% 
High risk 2.6% 34% 33.5% 
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the event of rebleed. The occurrence of rebleeding in our study is 
considerably higher compared to the 5.3% reported by Marco Soncini37. 
In our study qualifying  greater than 4 days of melaena as ‘continuing 
bleed/rebleed’ could have resulted in a possible overestimate of the 
actual rebleed. The exact duration of melaena that a single episode of 
UGIH would cause, is not defined and depends largely on the amount of 
bleed. “Fresh melaena” taken in a few studies41  as an event of rebleed is 
a loosely defined term and hence was not considered. 
DURATION OF HOSPITALISATION 
The Rockall score was correlated with the duration of 
hospitalisation and there was a highly significant correlation (p value 
0.000001). The average duration of hospitalisation was 6.01 days. The 
average duration of stay of patients in the high risk group was 8 days as 
compared to 4.6 days of the low risk group. The mean duration of 
hospitalisation in similar studies is compared below. 
 
Table 21: Duration of Hospitalisation with respect to Rockall scores 
among studies 
Mean duration of 
hospitalisation 
Our Study Marco soncini37 Robert A 
Enns49 
Total 6.01 d 6.06d 5.47d 
Low risk 4.6d 5.1d 3.6d 
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TRANSFUSION REQUIREMENTS            
Sixty two percent of the patients in this study required transfusion 
as compared to 54.1% reported by Marco Soncini’s study37. The no of 
transfusions was also a reflection of the calculated Rockall score. The 
correlation was significant with a p value of 0.0001. The Rockall score 
also reflected the urea value of the patients (p value0.000). Urea values 
are good indicators of the patients intravascular volume provided 
intrinsic renal failure is ruled out. BUN/creatinine ratio are indicators of 
the patients volume status50 and probably are better indicators of the 
patients intravascular volume status than the patient’s heart rate which 
can be influenced by the patients anxiety levels and haematemesis is 
indeed a terrifying event to the patient. The usage of the patients’ blood 
pressure is also not without reservations since the patients hypertensive 
status is not always known and hence an arbitrary level of <100mmHg 
to account for shock may actually underestimate the number of patients 
in hypovolemia. This is even more relevant in the Indian setting where 
the proportion of ‘undetected hypertensives’ is probably higher51 
compared to developed countries. Incorporating the patient’s 
BUN/creatinine or fractional excretion of Na (FENa) as a measure of the 
Intermediate risk 7.16d 5.9d 5.6d 
High risk 8d 7.2d 7.2d 
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volume status instead of the heart rate and blood pressure into a 
prognostic scoring system could probably solve these issues. Further 
studies are needed to see if incorporating these changes could increase 
the accuracy of such scoring systems.  
Tabulating the endoscopic diagnosis against the average Rockall 
score, showed that the value was highest in patients with Gastric 
carcinoma, followed by those with PUD, Mallory-Weiss tear and 
mucosal erosions, in that order. Since Rockall score is a prognostic 
indicator reflecting the chance of rebleed, outcome and duration of 
hospitalisation, it follows that the prognosis of the patients follows the 
same order. As expected, among the patients with Peptic Ulcer Disease 
the ones with Duodenal ulcer had a higher Rockall score than patients 
with Gastric Ulcer. 
 
 
 
ROCKALL SCORE AND OUTCOME 
There were three different outcomes in the patients under the 
study. The average Rockall score of the ones that were discharged after 
improvement was 2.47 and for the ones which were referred for surgical 
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management the score was 3.87. The single patient who died had the 
highest Rockall score of the three groups.                 
Based on the above results and observations, this study thereby 
concludes that Rockall score serves as a useful prognostic indicator in 
patients with non-variceal upper gastrointestinal bleeding. It correlates 
well with the rebleed, transfusion requirements, duration of 
hospitalisation, and their final outcome.  Hence, stratification according 
to this scoring system may aid in the better monitoring and 
managements of patients with Non-variceal Upper Gastrointestinal 
Haemorrhage. 
 
 
 
 
 
                      
 
CONCLUSION 
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1. Peptic Ulcer Disease is the most common cause of  Nonvariceal 
Upper Gastrointestinal Haemorrhage.  
 
2. Though among patients with peptic ulcer disease the commonest 
lesion found was gastric ulcer, duodenal ulcers had a greater 
chance of re-bleed and having a protracted course.  
 
3. Increasing age was associated with increased occurrence of re-
bleed and an increased duration of hospitalisation. 
 
4. Non variceal bleeding was more common in males. 
 
5. NSAID intake and alcohol are preventable predisposing factors 
for Non-variceal Upper Gastrointestinal Haemorrhage. 
 
6. Rockall score is useful in predicting the prognosis of the patients 
with NVUGIH. It correlates well with the re-bleed, duration of 
hospitalisation, transfusion requirements and outcome.  
 
 
 
 
 
SUGGESTIONS 
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1. The age criteria in Rockall score could be scaled down to suit the 
life expectancy of the Indian population. 
 
2. Including the FENa or BUN/creatinine as a measure of the volume 
status in a prognostic system might improve its accuracy. 
 
3. Stricter laws preventing the indiscriminate dispensing of drugs 
‘over-the-counter’ might decrease the incidence of drug induced 
GI bleeding.  
 
4. Increasing the Health awareness on the ill effects of alcohol might 
reduce the incidence of alcohol related causes of UGIH. 
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ABBREVIATIONS AND ACRONYMS 
 
UGIH   : Upper Gastrointestinal Haemorrhage 
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NVUGIH   : Non-Variceal Upper Gastrointestinal  
  Haemorrhage 
 
NSAID   : Non Steroidal Anti-inflammatory Drugs 
PUD   : Peptic Ulcer Disease 
MW   : Mallory Weiss 
GI  :  Gastro Intestinal  
SRH  : Stigmata of Recent Haemorrhage 
CA  : Carcinoma of the stomach 
ME  : Mucosal Erosions 
GU   : Gastric Ulcer 
DU  : Duodenal Ulcer 
OU   : Oesophageal Ulcer 
 
 
 
 
 
NON-VARICEAL  UGI BLEEDING -PROFORMA 
 
 
       Name:                                              Age:             Sex:     
                                                                                     
       Occupation:                          
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       I.P.No:                        Unit & Ward No.:             Address:   
                                                                                              Ph: 
 
DOA: 
 
DOE:                            Days of Hospital Stay: 
 
DOD: 
 
Diagnosis – Clinical       : 
                          Endoscopic : 
 
Clinical Presentation: 
 
Haematemesis  
Melaena  
Haematochezia  
Retching  
Abdominal pain  
Giddiness / LOC  
Palpitation  
Other systemic bleed  
 
Drug history: 
 
Anticoagulants  
Antiplatelet   
NSAIDs  
 
Personal history: 
 
Alcohol   
Smoking  
 
 
 
 
 
 
Past history: 
 
Previous UGI Bleed  
IHD  
CCF  
CKD  
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DCLD  
Known UGI malignanacy  
 
Clinical Findings: 
 
Pallor  
Tachycardia [HR>100]  
Systolic Hypotension [SBP<  
Altered sensorium  
P/A tenderness  
P.R  - Blood / melaena   
Blood in NGT aspirate  
 
Laboratory data: 
 
Hb  
Haematocrit  
Platelet count  
 
Bilirubin  
SGOT  
SGPT  
Total protein  
Albumin  
 
Urea  
Creatiniine  
 
 
No of units of Blood transfused: 
 
 
Oesophago-gastro-duodenoscopy: 
 
 
Rebleed during hospital stay: 
 
 
 
Outcome at discharge: 
 
Improved  
AMA  
Death & Cause  
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Status 10 days post presentation: 
 
        Rockall Score:
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